---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-455640"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2026-11-10T21:45:24+00:00"
generated_at: "2026-11-10T21:46:11.229071+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# InMed closes merger with Mentari; renamed Mentari Therapeutics (MTRI), Mentari holders own ~99%

## Summary
- Closed Nov 6, 2026 merger: InMed became Mentari Therapeutics, ticker MTRI on Nasdaq, after 1-for-10 reverse split and redomestication from British Columbia to Nevada.
- Exchange ratio was 0.20065 Company shares per Mentari common/Series A share; Mentari Series Seed preferred converted at 0.00020065 Company Series A preferred per share.
- Post-close fully diluted: legacy InMed holders ~1.0%, Mentari holders ~99.0%, after $490.0M PIPE of 215,042,178 shares and 7,317,328 pre-funded warrants.
- PIPE included $52.7M of principal/accrued interest on Mentari convertible notes; $290M tranche priced off $125M valuation, additional $200M at 152.8% of that price.
- CVRs: one per InMed share held Nov 5, 2026, paying 100% of net proceeds from legacy InMed business sale in first year and 90% in second; 2-year term, extendable to 15 years.

## SEC filing metadata
- accession: 0001193125-26-455640
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2026-11-10T21:45:24+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.03, 1.01, 2.01, 5.02, 9.01, 2.02, 3.02, 5.03, 5.01, 5.05, 5.06
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/d539218d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-455640
- JSON: https://secwatch.observer/filing/0001193125-26-455640.json
- Plain text: https://secwatch.observer/filing/0001193125-26-455640.txt

## Key facts
- Executive change
  Julianne Bruno was appointed as Director at InMed Pharmaceuticals Inc..
  - Role: Director
  source text: The newly constituted board of directors of the Company (the “ Board ”) has determined that each of Julianne Bruno, Michelle Pernice, Laura Sandler and Todd Shegog, each of whom is a current member of the Board, qualifies as an “independent director” as defined under the Nasdaq listing rules.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm
- Executive change
  Michelle Pernice was appointed as Director at InMed Pharmaceuticals Inc..
  - Role: Director
  source text: The newly constituted board of directors of the Company (the “ Board ”) has determined that each of Julianne Bruno, Michelle Pernice, Laura Sandler and Todd Shegog, each of whom is a current member of the Board, qualifies as an “independent director” as defined under the Nasdaq listing rules.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm
- Executive change
  Laura Sandler was appointed as Director at InMed Pharmaceuticals Inc..
  - Role: Director
  source text: The newly constituted board of directors of the Company (the “ Board ”) has determined that each of Julianne Bruno, Michelle Pernice, Laura Sandler and Todd Shegog, each of whom is a current member of the Board, qualifies as an “independent director” as defined under the Nasdaq listing rules.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm
- Executive change
  Todd Shegog was appointed as Director at InMed Pharmaceuticals Inc..
  - Role: Director
  source text: The newly constituted board of directors of the Company (the “ Board ”) has determined that each of Julianne Bruno, Michelle Pernice, Laura Sandler and Todd Shegog, each of whom is a current member of the Board, qualifies as an “independent director” as defined under the Nasdaq listing rules.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728328/000119312526455640/0001193125-26-455640-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.